3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
56
Lung Neoplasms
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasms
5
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Colonic Neoplasms
3
Advanced Solid Tumors
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Non-squamous Non-small Cell Lung Cancer
2
Mesothelioma
2
Meningeal Carcinomatosis
2
Melanoma
2
Lung Diseases
2
Esophageal Neoplasms
2
Carcinoma
2
Adenocarcinoma of Lung
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pathologic Processes
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
1
Pemetrexed
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Pemetrexed
×
30 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled